Last reviewed · How we verify
Brenzavvy (BEXAGLIFLOZIN)
Bexagliflozin inhibits SGLT2 to reduce renal glucose reabsorption and increase urinary glucose excretion.
At a glance
| Generic name | BEXAGLIFLOZIN |
|---|---|
| Sponsor | Theracosbio |
| Drug class | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2023 |
Mechanism of action
Bexagliflozin works by blocking the SGLT2 transporter in the kidneys, which is responsible for reabsorbing most of the glucose filtered by the renal glomerulus. By inhibiting this transporter, bexagliflozin lowers the amount of glucose that is reabsorbed, leading to more glucose being excreted in the urine.
Approved indications
- Diabetes mellitus type 2
Common side effects
- Increased urination
- Urinary tract infection
- Female genital mycotic infections
- Thirst
- Vaginal pruritus
- Hypoglycemia
- Polyuria
- Pollakiuria
- Micturition urgency
- Nocturia
- Dysuria
- Nitrite urine present
Key clinical trials
- Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (PHASE4)
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study (PHASE4)
- An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension (PHASE2,PHASE3)
- Bexagliflozin Drug/Drug Interaction Study With Digoxin (PHASE1)
- Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin (PHASE1)
- Bexagliflozin Efficacy and Safety Trial (PHASE3)
- Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brenzavvy CI brief — competitive landscape report
- Brenzavvy updates RSS · CI watch RSS
- Theracosbio portfolio CI